Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee
(NASDAQ: CBYL) Delayed: 0.68 --0 (-0%)
Previous Close $0.68    52 Week High $4.14 
Open $0.27    52 Week Low $0.44 
Day High $0.68    P/E N/A 
Day Low $0.68    EPS $0.00 
Volume 3,750